|
HOME >>
FAQs
What is the rationale for the demerger of the R&D company?
The R&D company will have projects in the areas of new
molecule and novel drug delivery systems, projects that will earn
intellectual property and
revenues from international markets. The rationale for the demerger is to
allow the right focus and resource commitment for long term projects that
have a different timeframe to completion.
Q-6. What are the
current projects in NCE and NDDS research?
The details of the current projects will be shared a
month prior to the listing of the new company. The NDDS projects are on four
platforms- CR/SR,
DPI, biodegradable membranes and targeted drug delivery. The NCE projects
follow a therapeutic analogue based approach in areas of known
biology.
Q-7.
How many factories are USFDA approved? How many factories are in the US?
Two API manufacturing factories in India, in Panoli
and Ahmednagar, hold USFDA approval. Three dosage form plants in the US-
Detroit (Caraco),
and plants at Bryan, Ohio and at Cranbury hold or will be shortly submitted
for USFDA approval. One dosage form plant in India, in Halol, holds
USFDA approval, for tablets, injectables and nasal sprays.
Q-8. How many
people work at Taj Pharmaceuticals Ltd.? How many people are in marketing?
How many people are in research?
Across the group, including subsidiaries, over 5,000
people work at Taj Pharmaceuticals Ltd.. About 500 people work in
marketing and sales in India,
and 260 in international markets (other than the US). About 500 scientist
work in research.
What is the breakdown by
type of business?
We are predominantly a dosage form company, with 84%
of sales from prescription products. APIs account for 16% of sales.
Domestic formulations, the sale of speciality
prescription brands in India,
account for about 55% of sales. International markets are about 40% of
sales.
of this, the US generic business at Caraco is 22%. (For the year ending
March 31, 2006)
Q-10. What are the
company's capex plans?
Typically Rs. 1,000
million are invested every year in capacity
expansion at the current sites. This is in addition to the Rs. 2,000 million
we invest
annually, at 10-12% of turnover, in R&D.
 |
India
